Tag: ICI

Find relevant news articles from other European projects, below:

CARAMBA  EURE-CART  CARAT Network ATECT PROCROP T2EVOLVE

Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:


Immunotherapy Web Featured Images 109

Browse this week's featured selection of scientific publications

A new selection of scientific publications relating to the latest developments in immunotherapy are added to our website weekly. Here are are a few highlights from this week.

Read more
Immunotherapy Web Featured Images 2

Immunotherapy Is on the Cusp of Major Breakthroughs in Multiple Myeloma

Just a decade ago, immune therapy for multiple myeloma barely existed as an idea. Since then, immune therapy has evolved rapidly and the field is on the verge of major improvements in outcomes.

Visit website
Immunotherapy Web Featured Images 100

Browse this week's featured selection of scientific publications

A new selection of scientific publications relating to the latest developments in immunotherapy are added to our website weekly. Here are this week's must-read highlights.

Read more
Immunotherapy Web Featured Images 106

Keytruda Closer to Expanded EU Approval for Pediatric Resistant Hodgkin’s Lympho...

Keytruda (pembrolizumab) has been recommended for approval in the European Union (EU) to treat adults and children, 3 years and older, with relapsed or refractory classical Hodgkin’s lymphoma (cHL) whose disease failed to respond to autologous stem cell transplant (ASCT) or who received at least two prior therapies when ineligible for ASCT.

Visit website
Immunotherapy Web Featured Images 109

Browse this week's featured selection of scientific publications

A new selection of scientific publications relating to the latest developments in immunotherapy are added to our website weekly. Here are are a few highlights from this week.

Visit website
Onclive8

Immunotherapy Inches Forward in Development of Myeloid Malignancies

Amer Zeidan, MD, MHS, discusses how survival for patients with acute myeloid leukemia and myelodysplastic syndrome remains poor, and although immunotherapy has been positioned as a holy grail, it would be preemptive to predict its future based on the number of small studies that have been performed to date.

Visit website
vjhemonic11

Effect of BMT status on decitabine plus ipilimumab in R/R MDS/AML

Jacqueline Garcia, MD, Dana-Farber Cancer Institute, Boston, MA, presents the safety and clinical activity data from a Phase I study (NCT02890329) of decitabine (DAC) plus ipilimumab (IPI) in patients with relapsed/refractory (R/R) myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) in the post bone marrow transplant (BMT) or treatment naïve setting.

Visit website
vjhemonic17

Current immune checkpoint inhibitor trials in AML/MDS

  Dec 07 2020 Tagged ICI, AML, MDS

Amer Zeidan, MBBS, MHS, Yale University School of Medicine and Yale Cancer Center, New Haven, CT, discusses several current trials of immune checkpoint inhibition in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) that were presented at ASH 2020.

Visit website
Immunotherapy Web Featured Images 46

ASH 2020 | Phase I trial of decitabine plus ipilimumab in R/R MDS & AML

Daniel DeAngelo, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the results of a Phase I trial (NCT02890329) of decitabine (DAC) in combination with ipilimumab (IPI) in patients with relapsed/refractory myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML), with or without prior allogeneic hematopoietic cell transplantation (allo-HCT).

Visit website
Immunotherapy Web Featured Images 32

EHA-SWG Scientific meeting on Immunotherapy: Checkpoint inhibition in hematologi...

  Dec 02 2020 Tagged ICI

Selected from the latest EHA-SWG Scientific Meeting on Immunotherapy, we present two lectures covering the use of immune checkpoint inhibitors (ICIs) in hematology. Peter Brossart explains the mechanism of action of these drugs and Paul Bröckelmann gives an updated overview of approved and emerging indications.  

Read more